Table 5.

T2D in relation to ER+ and ER− breast cancer incidence, within strata of BMI and waist–hip ratio

ER+ breast cancerER− breast cancer
CasesMV HR (95% CI)CasesMV HR (95% CI)
BMI < 30kg/m2
 No diabetes494Reference264Reference
 T2D210.86 (0.55–1.33)221.92 (1.22–3.04)
BMI ≥ 30 kg/m2
 No diabetes342Reference161Reference
 T2D511.07 (0.79–1.46)191.05 (0.64–1.72)
WHR < 85
 No diabetes532Reference274Reference
 T2D381.13 (0.81–1.60)221.55 (0.99–2.45)
WHR ≥ 85
 No diabetes210Reference114Reference
 T2D250.81 (0.53–1.24)161.26 (0.72–2.18)
  • NOTE: HRs adjusted for age, BMI at age 18, parity, age at first birth, age at menarche, duration of oral contraceptive use, duration of menopausal hormone use, and first degree family history of breast cancer. Pinteraction of T2D with BMI: 0.20 for ER+ and 0.05 for ER−. Pinteraction of T2D with WHR: 0.22 for ER+ and 0.40 for ER−.

  • Abbreviation: WHR, waist-hip ratio.